KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity
- Poirel, Laurent Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland
- Vuillemin, Xavier Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
- Juhas, Mario Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
- Masseron, Amandine Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
- Bechtel-Grosch, Ursina Department of Trauma Surgery, University Hospital of Zürich, Zürich, Switzerland
- Tiziani, Simon Institute of Intensive Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- Mancini, Stefano Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland
- Nordmann, Patrice Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland -
-
22.07.2020
Published in:
- Antimicrobial Agents and Chemotherapy. - 2020, vol. 64, no. 8, p. 10.1128/aac.00321-20
English
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three- amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.
- Faculty
- Faculté des sciences et de médecine
- Department
- Médecine 3ème année
- Language
-
- English
- Classification
- Biological sciences
- License
- License undefined
- Identifiers
-
- RERO DOC 329640
- DOI 10.1128/AAC.00321-20
- Persistent URL
- https://folia.unifr.ch/unifr/documents/309065
Other files
Statistics
Document views: 44
File downloads:
- poi_kcr_sm.pdf: 105
- poi_kcr.pdf: 182